Cyclic Adenosine Monophosphate
CAS 60-92-4
Cyclic Adenosine Monophosphate (CAS 60-92-4) is a pharmaceutical compound with 3 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 4925.47894736842 nM | 17 | - |
| - | IC50 | 42666.666666666664 nM | 3 | - |
| - | Kd | 4500 nM | 1 | - |
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| CNGA2 Cnga2 |
Agonist | 4.21 pEC50 | 10377344|7522482|7522325|22786723 |
| CNGA3 CNGA3 |
Agonist | 2.88 pKd | 8814292|12730238 |
| CNGA3 Cnga3 |
Agonist | 3.6 pKd | 11387380 |
| HCN1 Hcn1 |
Agonist | 7.199999809265137 pKd | 11331358|11524455 |
| HCN2 Hcn2 |
Agonist | 6.3 pKi | 9634236 |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Cyclic Adenosine Monophosphate used for in pharmaceutical contexts?
Cyclic Adenosine Monophosphate (CAS 60-92-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Cyclic Adenosine Monophosphate?
No adverse-event association or SIDER side-effect rows are rendered for Cyclic Adenosine Monophosphate in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Cyclic Adenosine Monophosphate also used in cosmetics?
No same-CAS cosmetics profile is rendered from the ingredients-table cross-reference for Cyclic Adenosine Monophosphate.
What clinical phase is Cyclic Adenosine Monophosphate in?
No phase 1-4 clinical development badge is rendered for Cyclic Adenosine Monophosphate because the matched compound identifier rows do not contain a max-phase value.